Corpus overview


MeSH Disease

Human Phenotype

Fever (17)

Pneumonia (7)

Anosmia (7)

Cough (6)

Falls (5)


    displaying 251 - 260 records in total 381
    records per page

    Evaluating the adequacy of Prima Covid-19 IgG/IgM Rapid Test SERO for the assessment of exposure to SARS-CoV-2 virus

    Authors: Giulia Di Lorenzo; Paolo Toniolo; Caterina Lurani; Luca Foresti; Chiara Carrisi

    doi:10.1101/2020.05.30.20117424 Date: 2020-06-03 Source: medRxiv

    The outbreak of the SARS-CoV-2 in early 2020 found health authorities worldwide unprepared to control the pandemic. The adoption of accurate, rapid and inexpensive methods to identify infected subjects in the general population is of paramount relevance for the control of the disease. We evaluated one of the available serological tests SERO, the Prima Lab Covid-19 IgG/IgM Rapid Tests SERO, on 739 volunteers. We first assessed the test's reproducibility by administering it twice on the same day on 104 subjects obtaining and overall score of 93 percent. Since the intensity of the color in the test line regions varies depending on the concentration of Covid-19 antibodies SERO in each sample and that the determination of the positivity depends strictly on the subjective assessment by the reader, after excluding the subjects whose color intensity was too tenuous to be deemed unquestionably positive by the reader the reproducibility increased to 96%. The test would not perform properly for 6 subjects for a very limited overall technical failure of 0.83%. For 138 subjects information was available regarding a previous Real Time PCR nasopharyngeal swab test performed elsewhere. The correspondence of positive results between the two tests was 90.58% (125/138). In spite of some limitation owing especially to the choice of a self selected population sample, we conclude that Prima Lab Covid-19 IgG/IgM Rapid Test SERO represents a low-cost, easily applicable and reproducible tool in detecting SARS-Cov-2 diffusion in the general population.

    High seroprevalence SERO for SARS-CoV-2 among household members of essential workers detected using a dried blood SERO spot assay

    Authors: Thomas W McDade; Elizabeth McNally; Aaron Zelikovich; Richard D'Aquila; Brian Mustanski; Aaron Miller; Lauren Vaught; Nina Reiser; Elena Bogdanovic; Katherine Fallon; Alexis Demonbreun

    doi:10.1101/2020.06.01.20119602 Date: 2020-06-02 Source: medRxiv

    Objective: Serological testing SERO is needed to investigate the extent of transmission TRANS of SARS-CoV-2 from front-line essential workers to their household members. However, the requirement for serum SERO/ plasma SERO limits serological testing SERO to clinical settings where it is feasible to collect and process venous blood SERO. To address this problem we developed a serological test SERO for SARS-CoV-2 IgG antibodies SERO that requires only a single drop of finger stick capillary whole blood SERO, collected in the home and dried on filter paper (dried blood SERO spot, DBS). Methods: An ELISA SERO to the receptor binding domain of the SARS-CoV-2 spike protein was optimized to quantify IgG antibodies SERO in DBS. Samples were self-collected from a community sample of 232 participants enriched with health care workers, including 30 known COVID-19 cases and their household members. Results: Among 30 individuals sharing a household with a virus- confirmed case TRANS of COVID-19, 80% were seropositive. Of 202 community individuals without prior confirmed acute COVID-19 diagnoses, 36% were seropositive. Of documented convalescent COVID-19 cases from the community, 29 of 30 (97%) were seropositive for IgG antibodies SERO to the receptor binding domain. Conclusion: DBS ELISA SERO provides a minimally-invasive alternative to venous blood SERO collection. Early analysis suggests a high rate of transmission among household TRANS members. High rates of seroconversion were also noted following recovery from infection. Serological testing SERO for SARS-CoV-2 IgG antibodies SERO in DBS samples can facilitate seroprevalence SERO assessment in community settings to address epidemiological questions, monitor duration of antibody SERO responses, and assess if antibodies SERO against the spike protein correlate with protection from reinfection.

    Immunochromatographic assays for COVID-19 epidemiological screening: our experience

    Authors: Andrea Bartolini; Margherita Scapaticci; Marina Bioli; Tiziana Lazzarotto; Maria Carla Re; Rita Mancini

    doi:10.1101/2020.05.28.20116046 Date: 2020-06-02 Source: medRxiv

    In March 2020, the World Health Organization (WHO) declared a pandemic caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2). Due to the absence of effective treatment or biomedical prevention, understanding potential post infection immunity has important implications for epidemiologic assessments. For this reason, increasing number of in vitro diagnostic companies are developing serological assays SERO to detect antibodies SERO against SARS-CoV-2, but most of them lack the validation by third parties in relation to their quality, limiting their usefulness. We submitted to serological screening SERO by two different immunochromatographic (IC) rapid testing SERO for detection of IgG and IgM against SARS-CoV-2, 151 asymptomatic TRANS or minimally symptomatic healthcare workers previously tested positive for SARS-CoV-2 RT-PCR in order to evaluate the performance SERO of rapid assays. Results showed discrepancies between molecular and IC results, and an inconsistency of immunoglobulins positivity patterns when compared to ELISA SERO/CLIA results, highlighting the absolute necessity of assays performance SERO validation before their marketing and use, in order to avoid errors in the results evaluation at both clinical and epidemiological level.

    Serological surveys in Reunion Island of the first hospitalized patients revealed that long-lived immunoglobulin G antibodies SERO specific against SARS-CoV2 virus are rapidly vanishing MESHD in severe cases

    Authors: Anthony Dobi; Etienne Frumence; Mahary LALARIZO RAKOTO; Gregorie Lebeau; Damien Vagner; Anne-Laure SANDENON SETEYEN; Claude Giry; Axelle Septembre-Malaterre; Marie-Christine Jaffar-Bandjee; Loic Raffray; Philippe Gasque

    doi:10.1101/2020.05.25.20112623 Date: 2020-06-02 Source: medRxiv

    Both cellular and humoral immunities are critically important to control COVID19 infection MESHD but little is known about the kinetics of those responses and, in particular, in patients who will go on to develop a severe form of the disease over several weeks. We herein report the first set of data of our prospective cohort study of 90 hospitalized cases. Serological surveys were thoroughly performed over 2 month period by assessing IgG and IgM responses by immunofluorescence, immunoblot, Western blot and conventional ELISA SERO using clinical RUN isolates of SARS-CoV-2 immobilized on 96 well plates. While the IgM and, unexpectedly, the IgG responses were readily detected early during the course of the disease (5-7 days post-first symptoms), our results (n=3-5 and over the full dilution set of the plasma SERO 1/200 to 1/12800) demonstrated a significant decrease (over 2.5-fold) of IgG levels in severe (ICU) hospitalized patients (exemplified in patient 1) by WB and ELISA SERO. In contrast, mild non-ICU patients had a steady and yet robust rise in their specific IgG levels against the virus. Interestingly, both responses (IgM and IgG) were initially against the nucleocapsid (50kDa band on the WB) and spreading to other major viral protein S and domains (S1 and S2. In conclusion, serological testing SERO may be helpful for the diagnosis of patients with negative RT-PCR results and for the identification of asymptomatic TRANS cases. Moreover, medical care and protections should be maintained particularly for recovered patients (severe cases) who may remain at risk of relapsing or reinfection. Experiments to ascertain T cell responses but although their kinetics overtime are now highly warranted. All in all, these studies will help to delineate the best routes for vaccination.

    A Novel Amplification-free SARS-CoV-2 Point-of-care Nucleic Acid Detection System based on Hybrid Capture Fluorescence Immunoassay SERO

    Authors: Daming Wang; Shaogui He; Xiaohui Wang; Min Chen; Li Li; Yang Lei; Jieli Zhang; Liwei Zhang; Xiao Hu; Xinhui Zheng; Jiawei Bai; Mingxuan Song; Yuguo Tang

    doi:10.21203/ Date: 2020-06-02 Source: ResearchSquare

    Herein we presented a novel, rapid and amplification-free SARS-CoV-2 nucleic acid detection system based on hybrid capture fluorescence immunoassay SERO ( HC-FIA MESHD) technology. The usage of the monoclonal antibody SERO S9.6 in recognizing DNA-RNA double-stranded hybrids enabled the conversion of nucleic acid testing into immunofluorescence carrying on a simple lateral flow dipstick. The established HC-FIA MESHD also exhibited satisfactory sensitivity SERO, specificity and great robustness. The clinical evaluation of HC-FIA MESHD kit and fluorescence reading device are further processed in three hospitals independently. The results of 734 samples from 670 subjects indicated high consistency between our HC-FIA MESHD and quantitative polymerase chain reaction based commercially available kit or clinical diagnosis according to Kappa statistics. Altogether, HC-FIA MESHD related method and commercial test kit show unparalleled advantages as time saving, amplification-free, high throughput and portable POCT molecular diagnosis, which facilitates its application as on-site Severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) nucleic acid detection in epidemic prevention and control worldwide, especially during the outbreak.

    Validation and Performance SERO Comparison of Three SARS-CoV-2 Antibody SERO Assays

    Authors: Shaolei Lu; Kimberly J Paiva; Ricky D Grisson; Philip A Chan; John Lonks; Ewa King; Richard C Huard; Diane L Pytel-Parenteau; Ga Hie Nam; Evgeny Yakirevich

    doi:10.1101/2020.05.29.124776 Date: 2020-05-30 Source: bioRxiv

    Serology testing of severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) is increasingly being used during the current pandemic of Coronavirus Disease MESHD 2019 (COVID-19). The clinical and epidemiologic utilities of antibody SERO-based SARS-CoV-2 testing are under debate. Characterizing these assays helps to understand the disease and provides scientific basis for deciding how to best use these assays. The study assessed one chemiluminescent assay (Abbott COVID-2 IgG) and two lateral flow assays (STANDARD Q [SQ] IgM/IgG Duo and Wondfo Total Antibody Test SERO). Validation included 113 blood SERO samples from 71 PCR-confirmed COVID-19 patients and 1182 samples from negative controls with potential interferences/cross-reactions, including 1063 pre-pandemic samples. IgM antibodies SERO against SARS-CoV-2 were detected as early as post- symptom onset TRANS days 3-4. IgG antibodies SERO were first detected post-onset days 5-6 by SQ assays. The detection rates increased gradually, and SQ IgG, Abbott IgG and Wondfo Total detected antibodies SERO from all the PCR-confirmed patients 14 days after symptom onset TRANS. Overall agreements between SQ IgM/IgG and Wondfo Total was 88.5% and between SQ IgG and Abbott IgG was 94.6% (Kappa = 0.75, 0.89). No cross-reaction with other endemic coronavirus infections MESHD were identified. Viral hepatitis HP Viral hepatitis MESHD and autoimmune samples were the main cross-reactions observed. However, the interferences/cross-reactions were low. The specificities were 100% for SQ IgG and Wondfo Total and 99.62% for Abbott IgG and 98.87% for SQ IgM. These findings demonstrate high sensitivity SERO and specificity of appropriately validated antibody SERO-based SARS-CoV-2 assays with implications for clinical use and epidemiological seroprevalence SERO studies.View Full Text

    A serological assay SERO to detect SARS-CoV-2 antibodies SERO in at-home collected finger-prick dried blood SERO spots

    Authors: Donna Grace Karp; Kenneth Danh; David Seftel; Peter Robinson; Cheng-ting Tsai

    doi:10.1101/2020.05.29.20116004 Date: 2020-05-30 Source: medRxiv

    Accurate surveillance of coronavirus disease MESHD 2019 (COVID-19) incidence requires large-scale testing of the population. Current testing methods require in-person collection of biospecimens by a healthcare worker, limiting access of individuals who do not have access to testing facilities while placing both the patient and healthcare worker at risk of exposure to infection. We report the development and validation of a at-home finger-prick dried blood SERO spot collection kit and an analysis method. We demonstrated 100% sensitivity SERO and specificity using at-home collected specimens across the US. Such methods may facilitate the conduct of unbiased serosurveys within hard to reach populations and help reduce the sample collection burden of serological testing SERO on both health care systems and individuals alike.

    Remarkable variability in SARS-CoV-2 antibodies SERO across Brazilian regions: nationwide serological household survey in 27 states

    Authors: Pedro Hallal; Fernando Hartwig; Bernardo Horta; Gabriel D Victora; Mariangela Silveira; Claudio Struchiner; Luis Paulo Vidaletti; Nelson Neumann; Lucia C Pellanda; Odir A Dellagostin; Marcelo N Burattini; Ana M Menezes; Fernando C Barros; Aluisio J Barros; Cesar G Victora

    doi:10.1101/2020.05.30.20117531 Date: 2020-05-30 Source: medRxiv

    Population based data on COVID-19 are essential for guiding policy. We report on the first wave of seroprevalence SERO surveys relying upon on household probabilistic samples of 133 large sentinel cities in Brazil, including 25,025 participants from all 26 states and the Federal District. Seroprevalence SERO of antibodies to SARS-CoV-2 SERO, assessed using a lateral flow rapid test SERO, varied markedly across the cities and regions, from below 1% in most cities in the South and Center-West regions to up to 25% in the city of Breves in the Amazon (North) region. Eleven of the 15 cities with the highest seroprevalence SERO were located in the North, including the six cities with highest prevalence SERO which were located along a 2,000 km stretch of the Amazon river. Overall seroprevalence SERO for the 90 cities with sample size of 200 or greater was 1.4% (95% CI 1.3-1.6). Extrapolating this figure to the population of these cities, which represent 25% of the country population, led to an estimate of 760,000 cases, as compared to the 104,782 cases reported in official statistics. Seroprevalence SERO did not vary significantly between infancy and age TRANS 79 years, but fell HP by approximately two-thirds after age TRANS 80 years. Prevalence SERO was highest among indigenous people (3.7%) and lowest among whites (0.6%), a difference which was maintained when analyses were restricted to the North region, where most indigenous people live. Our results suggest that pandemic is highly heterogenous, with rapid escalation in the North and Northeast, and slow progression in the South and Center-West regions.

    A SARS-CoV-2 serological assay SERO to determine the presence of blocking antibodies SERO that compete for human ACE2 binding

    Authors: James R. Byrnes; Xin X. Zhou; Irene Lui; Susanna K. Elledge; Jeff E. Glasgow; Shion A. Lim; Rita Loudermilk; Charles Y. Chiu; Michael R. Wilson; Kevin K. Leung; James A. Wells

    doi:10.1101/2020.05.27.20114652 Date: 2020-05-29 Source: medRxiv

    As SARS-CoV-2 continues to spread around the world, there is an urgent need for new assay formats to characterize the humoral response to infection. Convalescent serum SERO is being used for treatment and for isolation of patient-derived antibodies SERO. However, currently there is not a simple means to estimate serum SERO bulk neutralizing capability. Here we present an efficient competitive serological assay SERO that can simultaneously determine an individual's seropositivity against the SARS-CoV-2 Spike MESHD protein and estimate the neutralizing capacity of anti-Spike antibodies SERO to block interaction with the human angiotensin converting enzyme 2 (ACE2) required for viral entry. In this ELISA SERO-based assay, we present natively-folded viral Spike protein receptor binding domain (RBD)-containing antigens via avidin-biotin interactions. Sera are then supplemented with soluble ACE2-Fc to compete for RBD-binding serum SERO antibodies SERO, and antibody SERO binding quantified. Comparison of signal from untreated serum SERO and ACE2-Fc-treated serum SERO reveals the presence of antibodies SERO that compete with ACE2 for RBD binding, as evidenced by loss of signal with ACE2-Fc treatment. In our test cohort of nine convalescent SARS-CoV-2 patients, we found all patients had developed anti-RBD antibodies SERO targeting the epitope responsible for ACE2 engagement. This assay provides a simple and high-throughput method to screen patient sera for potentially neutralizing anti-Spike antibodies SERO to enable identification of candidate sera for therapeutic use.


    Authors: Isabel Galan; Maria Velasco; M Luisa Casas; M Jose Goyanes; Gil Rodriguez-Caravaca; Juan E Losa; Carmen Noguera; Virgilio Castilla; - Working Group Alcorcon COVID-19 investigators

    doi:10.1101/2020.05.29.20116731 Date: 2020-05-29 Source: medRxiv

    Background: Health-care workers (HCW) are at increased risk for SARS-CoV-2 infection MESHD, but few studies have evaluated prevalence SERO of antibodies SERO against SARS-CoV-2 among them. Objective: To determine the seroprevalence SERO against SARS-CoV-2 in all HCW. Methods. Cross-sectional study (April 14th- 27th , 2020) of all HCW at Hospital Universitario Fundacion Alcorcon, a second level teaching hospital in Madrid, Spain. SARS-CoV-2 IgG was measured by ELISA SERO. HCW were classified by professional category, working area, and risk for SARS-CoV-2 exposure. Results: Among 2919 HCW, 2590 (90.5%) were evaluated. Mean age TRANS was 43.8 years (SD 11.1) and 73.9% were females TRANS. Globally, 818 (31.6%) workers were IgG positive, with no differences for age TRANS, sex or previous diseases. Among them, 48.5% did not report previous symptoms. Seropositivity was more frequent in high (33.1%) and medium (33.8%) than in low-risk areas (25.8%, p=0.007), but no difference was found for hospitalization areas attending COVID-19 and non-COVID-19 patients (35.5 vs 38.3% p=NS). HCW with a previous SARS-CoV2 PCR positive test were IgG seropositive in 90.8%. By multivariate logistic regression analysis, seropositivity was associated with being physicians (OR 2.37, CI95% 1.61-3.49), nurses (OR 1.67, CI95% 1.14-2.46), or nurse- assistants (OR 1.84, CI95% 1.24-2.73), HCW working at COVID-19 hospitalization areas (OR 1.71, CI95% 1.22-2.40), non-COVID-19 hospitalization areas (OR 1.88, CI95% 1.30-2.73), and at the Emergency Room (OR 1.51, CI95% 1.01-2.27) Conclusions: Seroprevalence SERO uncovered a high rate of infection MESHD previously unnoticed among HCW. Patients not suspected of having COVID-19 as well as asymptomatic TRANS HCW may be a relevant source for nosocomial SARS-CoV-2 transmission TRANS.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.